Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Links relacionados
Similares em SciELO
uBio
Compartilhar
Acta bioquímica clínica latinoamericana
versão impressa ISSN 0325-2957versão On-line ISSN 1851-6114
Resumo
MARTINEZ-CABRERA, Ileana; MARTINEZ-CABRERA, Claudia; GARCIA ALVAREZ, Ángel e GARCIA CAPOTE, Ángela María. Un reto biomédico: facilitar la disponibilidad informativa acerca de la relación entre la microbiota intestinal, medicamentos y vacunas. Acta bioquím. clín. latinoam. [online]. 2023, vol.57, n.4, pp.5-5. ISSN 0325-2957.
Biomedical staff lacks a computer platform that summarises the main mechanisms of collaboration between intestinal microbes and humans, related to the absorption and transformation of drugs and vaccines and their ho-meostatic responses. For this reason, the aim of this work is to provide some evidences and recommendations for the design of a biomedical consultation platform, about the relationship between the microbiota and the effect of drugs or vaccines. These evidences will support the assessment for inclu¬sion of taxa and gut microbial abundance, as a part of clinical protocols of effectiveness. The survey carried out on a group of biomedical professionals, aimed at verifying the possibilities of access and specificity of this type of information made it possible to identify the main topics for the connection between drug groups, three-dimensional structure, modulators and mediators of the homeostatic response, biomarkers, inter-kingdom relationship and pathogenic mechanismsin such a way that all the human-microbiota “omics” information will be shown into a sub-platform within NCBI-NIH, which could be called Pharmacolobiomic or Pharmaco-metagenomic. The information is present in the databases contained in the NCBI, taking into account this search and filtering, from 28 628 references. Based on this proposal, the need for a pharmacometagenomic platform that summarises the role of the intestinal microbiota in the metabolism and effectiveness of drugs and vaccines was demonstrated, as well as having the systematic update for professionals about the microbiota as a biomarker, in clinical trial protocols.
Palavras-chave : Gut microbiota; Drugs; Vaccines; Metagenome; Pharmacology.